The somatic hypermutation (SHM) status of the clonotypic immunoglobulin heavy variable
(IGHV) gene is a critical biomarker for assessing the prognosis of patients with chronic …

Cytogenomic investigations of haematological neoplasms, including chromosome banding
analysis, fluorescence in situ hybridisation (FISH) and microarray analyses have become …

The value of genome-wide over targeted driver analyses for predicting clinical outcomes of
cancer patients is debated. Here, we report the whole-genome sequencing of 485 chronic …

Chronic lymphocytic leukaemia (CLL) is the most common leukaemia in the Western world
with an incidence of 4.2/100 000/year. The incidence increases to more than 30/100 …

Chronic lymphocytic leukemia (CLL) is characterized by the existence of subsets of patients
with (quasi) identical, stereotyped B-cell receptor (BcR) immunoglobulins. Patients in certain …

The typical genome of chronic lymphocytic leukemia (CLL) carries∼ 2000 molecular
lesions. Few mutations recur across patients at a frequency> 5%, whereas a large number of …

IMGT®, the international ImMunoGeneTics® information system founded in 1989 by Marie-
Paule Lefranc (Université de Montpellier and CNRS), marked the advent of …

Complex karyotype identified by chromosome-banding analysis has been shown to have
prognostic value in chronic lymphocytic leukemia (CLL). Genomic arrays offer high …

Emerging details of the gene expression and mutational features of canine lymphoma and
leukemia demonstrate areas of similarities and differences between disease subsets in the …

The Bruton's tyrosine kinase (BTK) inhibitor ibrutinib is inducing durable responses in
chronic lymphocytic leukemia (CLL) patients with refractory/relapsed disease or with TP53 …